Latest Administration News

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Energy World Corporation focused on advancing its capital raising and asset sales in Q3 2025, ending the quarter with $15 million in cash but no revenue generation.

Cycliq Group has completed a major e-commerce platform upgrade while preparing inventory for the critical Cyber November sales, reporting a 35% drop in quarterly customer receipts as it invests in future growth.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Pro-Pac Packaging has entered voluntary administration, securing relief to defer its financial reporting and annual general meeting obligations for up to two years. This move pauses key corporate governance duties as the company navigates its restructuring.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Auris Minerals advances its exploration efforts in Western Australia's Bryah Basin with a $3.2 million strategic placement, aiming to expand its geological team and accelerate copper, gold, and rare earth project identification.

Gale Pacific reports stabilising trading conditions in Q1 FY26 with a strategic U.S. operating model overhaul delivering significant cost savings, despite a slight dip in overall sales.

IODM Limited has reported a record-breaking first quarter for FY26, with cash receipts soaring 76% year-on-year, driven predominantly by explosive growth in its UK Education segment. The company also made strategic advances in North America and Japan, setting the stage for broader global expansion.

Sunshine Metals Limited reported a solid cash position of AUD 5.1 million at the end of Q3 2025, supported by a strong financing inflow that offsets ongoing exploration expenditures.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.